STOs: 87
Upcoming: 0
Main sale: 12
Funded: 7
Follow us on Telegramand Twitter

Agenus BEST

Our goal is to treat cancers with novel combinations

Description

Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations.

General information

Country of origin:
Most often it is the country whose citizens are the main part of the team, or the country where the main office is located.
United States

Legal

Company name:
Agenus Inc.
Country of incorporation:
Company address:
3 Forbes Road, Lexington, Massachusetts, 02421

Asset

Token rights:
Tokens give their owner the right to implement investment interests. It may be dividends, voting rights, etc.
Regulation(s):

Token details

Symbol:
BEST

Financial information

Fundraising goal:
Maximum goal for total funds raised in an STO.
$100,000,000
Min. investment:
$0

Additional links

Form D Filling (Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act)

Team members (16)

team
Garo Armen, PhD
Chairman and CEO
team
Jennifer Buell, PhD
Chief Operating Officer
team
Ozer Baysal
Chief Commercial Officer
team
Julie DeSander
Vice President, Business Development and Alliance Management
team
Anna Wijatyk, MD
Vice President of Clinical Development
team
Sunil Gupta, MBBS, FRCPC
Vice President of Regulatory & Pharmacovigilance
team
Alex Duncan, PhD
Chief Technology Officer
team
Christian Cortis, PhD
Chief Strategy Officer & Head of Finance
team
Evan Kearns, J.D.
Vice President & General Counsel
team
Christine Klaskin
Vice President, Finance & Principal Accounting Officer
team
Garo H. Armen, PhD
Chairman and CEO
team
Brian Corvese
Board of Directors
team
Wadih Jordan
Board of Directors
team
Ulf Wiinberg
Board of Directors
team
Timothy R. Wright
Board of Directors
team
Allison Jeynes-Ellis
Board of Directors

Advisors (4)

advisor
Robert Stein, MD, PhD
Senior R&D Advisor
advisor
Hagop Youssoufian, MD
Senior Clinical Strategist
advisor
Tyler Curiel, MD, MPH
Senior Strategist for Translational and Biomarker Development
advisor
Mary K. Pendergast
Advisor

Other STOs